Comparative Pharmacology
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESLICARBAZEPINE ACETATE versus QUDEXY XR.
ESLICARBAZEPINE ACETATE vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderateEslicarbazepine acetate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateEslicarbazepine acetate + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateCyclophosphamide + Eslicarbazepine acetate
"The metabolism of Eslicarbazepine acetate can be decreased when combined with Cyclophosphamide."
Clinical Note
moderateTerminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant
Phenytoin + Eslicarbazepine acetate
"The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin."